Results for tag: "Drug Eluting Implants"

Drug-eluting implants are a classification of medical devices that provide localized, sustained drug delivery to a specific area within the body, particularly after surgical procedures. These implants include drug-coated stents, beads, and other types of devices that release pharmaceutical agents over time directly at the target site. The purpose of these advanced medical devices is to enhance the healing process, prevent infection, reduce systemic drug exposure, and improve patient outcomes in various clinical areas such as cardiology, orthopedics, oncology, and ophthalmology. Cardiac stents that elute antiproliferative drugs, for example, are used to prevent restenosis after angioplasty. The market for drug-eluting implants has evolved in response to the need for better controlled drug release mechanisms and is characterized by continual clinical research, product innovation, and stringent regulatory hurdles that ensure efficacy and safety standards are met. Several major companies are prominent in the drug-eluting implants market. These include Boston Scientific Corporation, which is known for its drug-eluting stents, Medtronic PLC that offers various types of drug-releasing cardiac and spinal implants, and Abbott Laboratories, another key player in drug-eluting stent technology. Other notable companies include Bausch & Lomb Incorporated with drug-eluting ocular devices and Merck KGaA that provides drug-eluting beads for use in localized cancer treatments. Show Less Read more